Anesh Panchal

Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide

Claire Harrison, Adam J. Mead, Anesh Panchal et al. · Blood · 2017 · 167 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +3

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

John F. Seymour, Thomas J. Kipps, Barbara Eichhorst et al. · Blood · 2022 · 151 citations · Full text

Medicine, Oncology, Pharmacotherapy +15

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

Othman Al‐Sawaf, Can Zhang, Tong Lu et al. · Journal of Clinical Oncology · 2021 · 142 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial

Wei Shen Tan, Anesh Panchal, Laura Buckley et al. · European Urology · 2018 · 141 citations · Full text

Medicine, Oncology, Urology +7

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol et al. · Blood · 2021 · 37 citations

Medicine, Oncology, Pharmacology +12